Navigation Links
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
Date:1/18/2008

thritis and an EMEA regulatory application for HUMIRA to treat juvenile idiopathic arthritis. Clinical trials are currently underway evaluating the potential of HUMIRA in ulcerative colitis. HUMIRA is also approved for reducing signs and symptoms in patients with active AS. HUMIRA is approved for reducing the signs and symptoms and inducing and maintaining clinical remission in adults with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy and reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.

Abbott's Commitment to Immunology

Abbott is focused on the discovery and development of innovative treatments for immunologic diseases.

More information about HUMIRA, including full prescribing information and Medication Guide, is available on the Web site http://www.Rxabbott.com or in the United States by calling Abbott Medical Information at 1-800-633-9110.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals and devices. The company employs 65,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... and HERZLIYA PITUACH, Israel , July ... OMX First North Premier, Stockholm : ... has initiated the screening of patients for a Phase ... and efficacy of bertilimumab in the treatment of moderate ... 10-15 patients who will receive two bertilimumab infusions, at ...
(Date:7/29/2014)... YORK , July 29, 2014 /PRNewswire-iReach/ -- ... the basis of products, methods, applications, end users, ... highest growth in the microbial identification market. This ... consumable costs (per test) and the time required ... and continuous technological advancements. Furthermore, genotypic methods have ...
(Date:7/29/2014)... 2014 Amgen (NASDAQ: AMGN ) ... 2014. Key results include: , Total revenues increased ... sales growth driven by strong performance across the portfolio, ... Prolia ® (denosumab) and XGEVA ® (denosumab). ... driven by higher revenues and a significant increase in ...
Breaking Medicine Technology:Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 3Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 4Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25
... 21, 2012  Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ... conferences: , Citi 2012 Global Healthcare Conference at ... , RBC Capital Markets, Healthcare Conference at 9:00 ... The sessions may be accessed through the Company,s ...
... 21, 2012  Acuo Technologies®, the leader in high-performance ... management and data migration, announces another year of ... achieved sales growth of over 90% from the ... from fiscal year end 2010.  The company signed ...
Cached Medicine Technology:Regeneron Announces February 2012 Investor Conference Presentations 2Acuo Technologies Announces Another Significant Growth Year in Sales to Further the Company's Market Leading Position 2
(Date:7/30/2014)... July 30, 2014 According to the Yeast ... is a comprehensive guide that will help candida sufferers get ... few weeks. This book uncovers to readers the truth about ... addition, inside this book, people will discover natural and safe ... such as itching, burning, and irritation of the vagina or ...
(Date:7/30/2014)... WA (PRWEB) July 30, 2014 According to ... Vkool.com, this is a comprehensive guide that teaches people how ... few weeks. The book uncovers to readers the horrible truth ... in its review that inside this book, people will learn ... such as inflammation, asthma, and nasal infections. , Nasal Polyps ...
(Date:7/30/2014)... According to the Critical Bench Program 2.0 Pdf review recently ... men who want to discover how to increase their ... a few months. Inside this book, learners will discover a ... avoid the aches and pains. , Vkool reveals in its ... the reason why stretching and warming up is so important ...
(Date:7/30/2014)... 30, 2014 Neil Haley, the Total Tutor ... GJ Reynolds to find out about what is branding, how ... best brand. , Reynolds is an original founding member of ... Vi Millionaire, and CEO of Simply G Media. He has ... You!" and holds the distinction of completing the Dale Brown ...
(Date:7/30/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) ... therapy note templates. Healthcare providers can now create ... all while meeting the HIPPA security requirements.     , ... (EMR) consist of psychological intake forms, treatment plan ... SOAP and DAP note formats are also available. ...
Breaking Medicine News(10 mins):Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 2Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 3Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 3Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 2Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 3Health News:Entrepreneur and Vi Millioniare GJ Reynolds Discusses How to Improve Your Brand on the Simply G Radio Show, a Division of the Simply G Media Network 2Health News:My Clients Plus Announces Over 80 Online Therapy Notes to Help Healthcare Providers Go Paperless 2
... LIVERMORE, Calif. , Feb. 1 The ... recently featured headline stories about a clinical study that is ... surprised by the attention this study is getting from the ... Officer of Halt Medical, Inc., a medical technology company headquartered ...
... could lead to false positives -- adding stress to ... unnecessary follow-up treatment and dietary restrictions. But the ... risk of mental retardation, disability or death outweigh the ... research published today in the February issue of the ...
... ... Santen Inc., as its 2010 president. , ... San Francisco (Vocus) -- Ophthalmic Women Leaders (OWL) has appointed ... , , ,Prior to her appointment as president, Gleeson previously served as chair of ...
... , ... solution to overcome the obstacle of health insurance. , ... (PRWEB) February 1, 2010 -- EasyToInsureME announces a new solution to ... are very afraid. This past week states like Virginia and Pennsylvania are already making laws ...
... A ... ... A report on pedestrian accident statistics released by Elmhurst Hospital Center shows that the number of ... report is being analyzed by New York personal injury attorneys to help their clients., ...
... , Feb. 10 Event With Celebrity Panel To Discuss ... The increased scrutiny of the fashion industry and its use of ultrathin ... say that the fashion industry is at least partially responsible for "girls, ... the Girl Scouts of the USA . , The nationwide survey, ...
Cached Medicine News:Health News:Benefits outweigh risks associated with newborn screening for disorder 2Health News:Ophthalmic Women Leaders (OWL) Names Pamela Gleeson, CFO Of Santen Inc., as 2010 President 2Health News:Recent Shoppers Face Health Insurance Obstacles 2Health News:Recent Shoppers Face Health Insurance Obstacles 3Health News:No Surprise to David Perecman And Other Personal Injury Attorneys, Vehicles Lead All Causes of Injury at New York Hospital 2Health News:No Surprise to David Perecman And Other Personal Injury Attorneys, Vehicles Lead All Causes of Injury at New York Hospital 3Health News:Nationwide Study Finds That Teenage Girls Have Mixed Feelings About the Fashion Industry 2Health News:Nationwide Study Finds That Teenage Girls Have Mixed Feelings About the Fashion Industry 3Health News:Nationwide Study Finds That Teenage Girls Have Mixed Feelings About the Fashion Industry 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: